ReviveMed is an MIT spinout, artificial intelligence (AI)-driven drug discovery platform by uniquely leveraging data form small molecules or metabolites in the human body. Located in the heart of biotech innovation in Cambridge, ReviveMed uniquely overcomes the difficulties of identifying a large set of metabolites for each patient, based on technology that our team developed at MIT and published in Nature Methods. Our AI platform further combines the data from small molecules with other molecular data, and translates these data into novel therapeutic insights for drug discovery.
Currently, ReviveMed is collaborating with tier-one pharmaceutical companies and pursuing internal drug discovery, initially focused on metabolic diseases, including non-alcoholic fatty liver.